Immuno-Biological Laboratories Co., Ltd. (4570) Stock Statistics & Valuation Metrics

Immuno-Biological Laboratories Co., Ltd. has a market cap or net worth of JPY 8.67B. The enterprise value is JPY 10.35B.

Market Cap

JPY 8.67B

Enterprise Value

JPY 10.35B

Immuno-Biological Laboratories Co., Ltd. has 9,314,590 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

9,314,590

Owned by Insiders

―

Owned by Institutions

―

Immuno-Biological Laboratories Co., Ltd.’s return on equity (ROE) is 0.18 and return on invested capital (ROIC) is 13.81%.

Return on Equity (ROE)

0.18

Return on Assets (ROA)

0.15

Return on Invested Capital (ROIC)

13.81%

Return on Capital Employed (ROCE)

0.15

Revenue Per Employee

18.61M

Profits Per Employee

6.09M

Employee Count

54

Asset Turnover

0.47

Inventory Turnover

0.80

The current PE Ratio of Immuno-Biological Laboratories Co., Ltd. is 22.84. Immuno-Biological Laboratories Co., Ltd.’s PEG ratio is 1.34.

PE Ratio

22.84

PS Ratio

7.89

PB Ratio

4.33

Price to FCF

0.00

Price to Operating Cash Flow

0.00

PEG Ratio

1.34

In the last 12 months, Immuno-Biological Laboratories Co., Ltd. had revenue of 1.00B and earned 329.01M in profits. Earnings per share was 35.33.

Revenue

1.00B

Gross Profit

700.28M

Operating Income

281.28M

Pretax Income

300.56M

Net Income

329.01M

EBITDA

299.82M

Earnings Per Share (EPS)

35.33

In the last 12 months, operating cash flow was 0 and capital expenditures 0, giving a free cash flow of 0 billion.

Operating Cash Flow

0

Free Cash Flow

0

Free Cash Flow per Share

0.00

Immuno-Biological Laboratories Co., Ltd. pays an annual dividend of JPY 6.00, resulting in a dividend yield of 0.65%

Dividend Per Share

JPY 6.00

Dividend Yield

0.65%

Payout Ratio

N/A

Free Cash Flow Yield

0.00%

Earnings Yield

4.31%

Beta

1.02

52-Week Price Change

52.58%

50-Day Moving Average

1087.64

200-Day Moving Average

1196.27

Relative Strength Index (RSI)

36.62

Average Volume (3m)

128.03K

Immuno-Biological Laboratories Co., Ltd. upcoming earnings date is Feb 10, 2027, TBA (Not Confirmed).

Last Earnings Date

Nov 11, 2026

Next Earnings Date

Feb 10, 2027

Ex-Dividend Date

Mar 30, 2026

Immuno-Biological Laboratories Co., Ltd. as a current ratio of 5.68, with Debt / Equity ratio of 9.61%

Current Ratio

5.68

Quick Ratio

4.31

Debt to Market Cap

0.01

Net Debt to EBITDA

-2.71

Interest Coverage Ratio

211.01

In the past 12 months, Immuno-Biological Laboratories Co., Ltd. has paid -28.45M in taxes.

Income Tax

-28.45M

Effective Tax Rate

-0.09

Immuno-Biological Laboratories Co., Ltd. EV to EBITDA ratio is 21.19, with an EV/FCF ratio of 0.00.

EV to Sales

7.23

EV to EBITDA

21.19

EV to Free Cash Flow

0.00

EV to Operating Cash Flow

0.00

Immuno-Biological Laboratories Co., Ltd. has JPY 907.94M in cash and marketable securities with JPY 171.81M in debt, giving a net cash position of JPY 736.13M billion.

Cash & Marketable Securities

JPY 907.94M

Total Debt

JPY 171.81M

Net Cash

JPY 736.13M

Net Cash Per Share

JPY 79.03

Tangible Book Value Per Share

JPY 202.57

Gross margin is 72.07%, with operating margin of 31.09%, and net profit margin of 34.54%.

Gross Margin

72.07%

Operating Margin

31.09%

Pretax Margin

31.93%

Net Profit Margin

34.54%

EBITDA Margin

32.84%

EBIT Margin

31.09%

The average price target for Immuno-Biological Laboratories Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target

―

Price Target Upside

―

Analyst Consensus

―

Analyst Count

―

Revenue Growth Forecast

7.10%

EPS Growth Forecast

17.17%

Smart Score

―

AI Score

70